Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive News from MarketBeat.com Pfizer Adds to Its Big Bet on Weight Loss DrugsSubmitted by Jordan Chussler. Publication Date: 12/16/2025. 
Summary - The health care sector has led the S&P 500 over the three months, but Pfizer has lagged of late, slipping 5% since the start of October.
- As the Big Pharma company continues to struggle to replace COVID-19 vaccine revenue, it is heavily learning into the semaglutide and GLP-1 weight loss drug trend.
- Last week, the company signed a $2.1 billion licensing agreement with a Chinese pharma company to develop its early-stage weight loss pill.
Health care stocks have been on a run lately, leading the S&P 500's 11 sectors over the past three months with a gain of 11.55%. Unfortunately for some investors, that recent rally has not included all of the Big Pharma mainstays. Pfizer (NYSE: PFE), the maker of Chantix, Eliquis and Paxlovid, has seen its shares slide about 5% since the start of October. By comparison, other mega-cap pharmaceutical companies such as Johnson & Johnson (NYSE: JNJ), Regeneron Pharmaceuticals (NASDAQ: REGN), and Eli Lilly (NYSE: LLY) are up nearly 14%, 24%, and 25%, respectively, over the same period. WARNING: Do Not Buy AI Stocks
While NVIDIA wobbles and the Magnificent 7 cool off, there's a backdoor AI play most investors are missing. It's not software. It's not chips. It's the physical infrastructure. The land, buildings, and power that make AI possible. Former Presidential Advisor Brad Thomas says Trump's Executive Orders are about to ignite a boom in this sector. And a small handful of companies are positioned to dominate. He names his top pick - completely free - in this time-sensitive video. Get the name and ticker of his #1 "Mandatory Payout" stock to buy now, FREE And despite Pfizer making headlines on Nov. 13 after acquiring obesity biotech Metsera in a $10 billion deal, the stock has only managed a 0.23% gain since then. The nearly 177-year-old biopharma company is once again looking to expand its role in the weight loss drug market, with management and shareholders alike hoping that doing so can help offset lost revenue as demand for mRNA-based COVID-19 vaccines wanes. Pfizer Looks to Gain Market Share After Enormous Deal With YaoPharma On Tuesday, Dec. 9, Pfizer struck a $2.1 billion licensing deal with China's YaoPharma to develop a GLP-1 weight loss pill that is in early-stage development. The drug works similarly to Wegovy, the game-changing weight-loss injection from competitor Novo Nordisk (NYSE: NVO). Of course, news of a yet-to-be-approved weight loss pill may not be enough to move the stock in the short term; it does underscore the company's commitment and momentum in the obesity treatment market. The agreement calls for Pfizer to pay a $150 million upfront fee to YaoPharma's parent company, Shanghai Fosun Pharmaceutical, which has an $8.4 billion market cap. Additionally, Pfizer could pay YaoPharma up to $1.94 billion in milestone payments tied to development and approval progress, plus royalty payments on sales if the drug is ultimately approved. Those milestone payments will be contingent on YaoPharma successfully advancing the weight loss pill through phase-one trials, after which Pfizer will take control of later-stage development. Pfizer also plans to conduct combination studies — currently in mid-stage development — pairing YaoPharma's pill with Pfizer's own GIP receptor agonist. Eli Lilly has pursued a similar strategy with its weight-loss treatment Zepbound and diabetes drug Mounjaro, targeting both GLP-1 and GIP. Pfizer Is Positioning Itself for the Future of the Weight Loss Drug Market The deal is noteworthy because it demonstrates how aggressively the company's leadership is pursuing a long-term role in the GLP-1 and broader obesity treatment market. Pfizer's management has shown it is willing to invest roughly $10.1 billion over the past month to that end as it targets a rapidly expanding industry. Forecasts from market analysis firm Grand View Research suggest the GLP-1 weight loss drug market will grow at a compound annual growth rate (CAGR) of 18.54% from 2025 to 2030 — from under $14 billion at the start of this year to an estimated $48.84 billion by 2030. Grand View Research found that North America accounts for the largest revenue share, representing more than 75% of the GLP-1 agonists market. While other obesity interventions exist, including lifestyle changes and bariatric surgery, GLP-1 drugs remain the preferred option among many physicians and patients. Patient Investors Can Enjoy PFE's Sizable Dividend Shareholders are hoping Pfizer's push into the weight loss market pays off after the stock has fallen more than 31% over the past five years. Much of that decline followed a drop in COVID-vaccine sales: year-over-year revenue growth swung from more than 95% at the end of 2021 to a decline exceeding 41% by the end of 2023. Last year, Pfizer posted a modest rebound, with revenue rising nearly 7%. Meanwhile, the stock's dividend yield has helped ease some investors' concerns. Pfizer remains a consistent dividend payer with a current yield of 6.65% — $1.72 per share annually. That payout has increased for 16 consecutive years, making the stock attractive to income investors despite a roughly 100% payout ratio that raises questions for some. For investors comfortable with a longer time horizon and bullish on the near- and mid-term potential of prescription weight loss drugs, Pfizer can provide income while serving as a speculative play in the GLP-1 space. However, growth-focused investors may be wary after another year of lackluster performance. Analysts' average 12-month price target implies roughly 10% upside from the current price and carries a consensus Hold rating. Meanwhile, short interest has been steadily rising as the stock attracts more bearish bets. Currently, about $3.58 billion worth of the float is shorted — nearly 84% more than PFE's short position at the end of January 2025.
| 
